NCT03411941

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Observational, Retrospective Study to Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 116 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

There is a need to investigate the effectiveness of IVT aflibercept injection in routine clinical practice. The aim of this study is to collect 12-month real-world clinical data from treatment-naïve nAMD patients who started first-line treatment with IVT aflibercept injection, according to the SmPC (Summary of Product Characteristics) and the SERV (Spanish Society of Retina and Vitreous) guidelines. The effectiveness of IVT aflibercept will be assessed by the changes in VA (Visual Acuity) and CRT (Central Retinal Thickness) during treatment.

Conditions

• Macular Degeneration

Interventions

Type	Name	Description
DRUG	Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)	IVT(Intravitreal) aflibercept treatment in routine clinical practice.

Timeline

• Start date: 2018-02-28
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2018-01-26
• Last updated: 2019-12-05

Locations

1 site across 1 country: Spain